ReviewFrontiers in cellular and infection microbiology2026
Crosstalk between the microbiome and the mucosal immunoglobulin A system in the lung, in health and disease.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lung, and more specifically the airway epithelium, is continuously exposed to a wide range of inhaled environmental agents. Acting as a frontline physical and biochemical barrier, the airway epithelium orchestrates early host defense mechanisms, among which immunoglobulin A (IgA) plays a central role. Long considered sterile, the healthy lung is now recognized as a complex mucosal ecosystem harboring diverse and dynamic microbial communities, including bacteria, fungi, viruses, and archaea. Although the lung microbiome is generally transient and low in biomass, accumulating evidence suggests that it contributes to pulmonary homeostasis by supporting immune system maturation, preserving structural tissue integrity, and limiting pathogen colonization. How immune homeostasis is maintained in this constantly challenged environment remains however a central and largely unanswered question. This review synthesizes current state-of-the-art knowledge on the origin, composition, and functional determinants of the lung microbiome, with a specific focus on its bidirectional interplay with secretory IgA. We discuss microbiota-specific IgA responses, factors influencing IgA-microbiome interactions, and how these processes are disrupted in chronic and inflammatory lung diseases. Finally, we highlight major knowledge gaps and explore emerging therapeutic perspectives targeting IgA-microbiome crosstalk to restore pulmonary immune homeostasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.